Caris Life Sciences Target Now(TM) Targets Cancer Treatment Selection
Published: Nov 30, 2011
(Click here for details)
A new evidence-based molecular profiling system -- called Caris Target Now(TM) -- is bringing about dramatic changes in the personalization of cancer care.
In this video, Sandeep Reddy, MD, joins Sandra Fehrman, a cancer survivor, to discuss the role of molecular profiling in cancer care.
IRVING, TX--(Marketwire - November 29, 2011) -
Caris Target Now
Caris Life Sciences
A new evidence-based molecular profiling system -- called Caris Target Now™ -- is bringing about dramatic changes in the personalization of cancer care.
No two cancers are alike and cancer treatment plans shouldn't be either. Treatment that works well for one person may be ineffective for another, because each patient's cancer has different genetics. Caris Target Now™ makes it possible to detect those differences, match a tumor's genetics with specific drugs more likely to be effective, and flag therapies with less chance of working.
Personalized cancer treatment like this can increase quality of life, uncover treatments previously not considered, and cut healthcare costs.
One multicenter study conducted by Caris Life Sciences, and published in the Journal of Clinical Oncology, showed that Caris Target Now™ molecular profiling increased progression free survival from various cancers, including late-stage cancer, in 27 percent of 86 patients studied who had their therapy selected this way, versus the previous therapy on which they had progressed.
Sandeep K. Reddy, MD, oncology expert and clinical associate professor of medicine, Geffen/UCLA School of Medicine, discusses Caris Target Now™, and Sandra Fehrman, a cancer patient, explains how this technology helped to extend and enhance her life, in this moving video.